Novo Nordisk Gulf receives prestigious Best Places to Work Certification in Kuwait, Qatar, Bahrain, and Oman for 2024 ...

Shares in telehealth group Hims & Hers Health (NYSE:HIMS) dropped in premarket US trading on Thursday after federal drug ...

Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and ...

Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

It took GLP-1 medications like Ozempic just seven years to surpass insulin as the the second most common treatment for type 2 ...

Pharmaceutical giant Pfizer is set to reduce its workforce in Ireland as it faces ongoing challenges in the wake of the COVID ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...